Lumen Technologies' stock price target has been revised, with fair value per share rising slightly from $5.20 to $5.28. This ...

Alnylam Pharmaceuticals reported third-quarter 2025 earnings, achieving US$1.25 billion in revenue and a net income of US$251.08 million, while also raising full-year revenue guidance to between US$2.